UBS has lowered its price target for Lululemon Athletica Inc. to $335 from $376, maintaining a Neutral rating amid concerns over the company's growth outlook. Despite strong fourth-quarter earnings and revenue exceeding forecasts, analysts are skeptical about Lululemon's ability to achieve significant growth, with projections indicating a low single-digit sales CAGR in the U.S. for fiscal year 2025. Other firms, including Needham and JPMorgan, have also adjusted their price targets, reflecting cautious sentiment regarding future margins and growth potential.